DoMore Diagnostics

DoMore Diagnostics uses digital biomarkers developed with AI to make personalized treatment decisions simple and accessible for cancer patients. Its unique digital biomarkers predict patient outcomes from routine tumor tissue slides and can be seamlessly integrated into pathologists’ existing workflow. The lead product Histotype Px® Colorectal is a CE-IVDD marked outcome prediction marker for stage II and III colorectal cancer that informs the decision of whether to provide adjuvant chemotherapy following surgical resection of the tumor.